Omeprazole in Zollinger–Ellison Syndrome
- 22 March 1984
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 310 (12) , 758-761
- https://doi.org/10.1056/nejm198403223101205
Abstract
We studied the effect of omeprazole, a benzimidazole inhibitor of gastric acid secretion, in patients with Zollinger–Ellison syndrome. In five patients ingestion of 80 mg of omeprazole inhibited gastric acid secretion by 26 to 100 per cent after 6 hours and by 76 to 100 per cent after 24 hours. Seven patients were continuously treated with omeprazole once or twice daily for 8 to 19 months (average, 14). Six of these seven had symptoms that were resistant to high doses of histamine H2-receptor antagonists, and the seventh could not take high doses of cimetidine because of a possible drug-related increase in the serum creatinine concentration. Symptoms resolved in all patients within two weeks, and peptic lesions were healed at endoscopy after four weeks. All patients remained free of symptoms, and gastric acid secretion continued to be markedly inhibited by omeprazole therapy.This publication has 5 references indexed in Scilit:
- Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.Gut, 1983
- Inhibition of acid secretion in isolated gastric glands by substituted benzimidazolesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1982
- Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPaseNature, 1981